Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

4E3O

Crystal structure of AmpC beta-lactamase in complex with a small chloromethyl sulfonamide boronic acid inhibitor

Summary for 4E3O
Entry DOI10.2210/pdb4e3o/pdb
Related4E3I 4E3J 4E3K 4E3L 4E3M 4E3N
DescriptorBeta-lactamase, ({[(chloromethyl)sulfonyl]amino}methyl)boronic acid, PHOSPHATE ION, ... (4 entities in total)
Functional Keywordsampc beta-lactamase, class c, cephalosporinase, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
Biological sourceEscherichia coli
Cellular locationPeriplasm: P00811
Total number of polymer chains2
Total formula weight79930.55
Authors
Eidam, O.,Shoichet, B.K. (deposition date: 2012-03-09, release date: 2012-09-26, Last modification date: 2024-10-30)
Primary citationEidam, O.,Romagnoli, C.,Dalmasso, G.,Barelier, S.,Caselli, E.,Bonnet, R.,Shoichet, B.K.,Prati, F.
Fragment-guided design of subnanomolar beta-lactamase inhibitors active in vivo.
Proc.Natl.Acad.Sci.USA, 109:17448-17453, 2012
Cited by
PubMed Abstract: Fragment-based design was used to guide derivatization of a lead series of β-lactamase inhibitors that had heretofore resisted optimization for in vivo activity. X-ray structures of fragments overlaid with the lead suggested new, unanticipated functionality and points of attachment. Synthesis of three derivatives improved affinity over 20-fold and improved efficacy in cell culture. Crystal structures were consistent with the fragment-based design, enabling further optimization to a K(i) of 50 pM, a 500-fold improvement that required the synthesis of only six derivatives. One of these, compound 5, was tested in mice. Whereas cefotaxime alone failed to cure mice infected with β-lactamase-expressing Escherichia coli, 65% were cleared of infection when treated with a cefotaxime:5 combination. Fragment complexes offer a path around design hurdles, even for advanced molecules; the series described here may provide leads to overcome β-lactamase-based resistance, a key clinical challenge.
PubMed: 23043117
DOI: 10.1073/pnas.1208337109
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.6 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon